Summary Suppressor gene loci involved in the development of hepatocellular carcinoma (HCC) have not been fully identified. The aim of this study was to look for consistent allele loss, or loss of heterozygosity (LOH), in HCC which might represent such gene loci. We have prepared DNA from tumour and non-tumour material from 16 patients with HCC (nine with and seven without liver cirrhosis). Tumour DNA was compared with non-tumour DNA by Southern analysis performed with a panel of 22 probes recognising restriction fragment length polymorphisms assigned to chromosomes 1, 4, 5, 7, 9, 11, 12, 13, 14, 16, 17, 
Hepatocellular carcinoma (HCC) is a major cause of death from malignancy in the world, with a particularly high incidence in the Far East and Africa where hepatitis B virus (HBV) infection, established as an aetiological agent, is common. In Western countries the incidence is lower but increasing. Most HCC are beyond radical resection when detected, and all other forms of the currently available therapies are rarely beneficial. For these reasons the cellular and molecular changes leading to HCC demand study, with a view to identification of patients at particular risk, earlier detection of tumours and, in the long-term, successful therapy.
In most tumours carcinogenesis is the result of an interaction between genetic and environmental factors, and appears to be a multistep process. Several mutations may be necessary and in broad terms two interacting mechanisms seem to be involved: oncogene activation or mutation, and loss of tumour suppressor factors. Mutant oncogenes introduced into cultured cells are capable of inducing malignant transformation. In patients with tumours, mutation of an oncogene may allow production of proteins which perpetuate proliferation. Evidence is accumulating now that excess proliferation is opposed by the products of tumour suppressor genes, and that these are at least as important as oncogenes in carcinogenesis. Their presence was predicted by Knudson's model for sporadic and inherited forms of retinoblastoma (Knudson, 1971) . The gene involved in retinoblastoma has now been identified and the gene product characterised (Friend et al., 1986; Lee et al., 1987) . Loss of tumour suppressor has now been implicated in Wilms' tumour (Rose et al., 1990) , acoustic neuroma (Seizinger et al., 1986) and also carcinomas of the colon (Fearon et al., 1990; Kinzler et al., 1991) , lung (Kok et al., 1987) and breast (Mackay et al., 1988) .
For the common tumours such as carcinomas of the colon, breast and lung, the evidence for loss of tumour suppressor genes has accumulated from the demonstration of a consistent loss of a region of genomic DNA in tumour tissue ('allele loss') when compared with the individual's normal DNA. Allele loss, or loss of heterozygosity (LOH), on chromosomes 5,17 and 18 has been found in colonic carcinoma (Vogelstein et al., 1988) . Introduction of a normal chromosome 5 or 18 into this tumour, in vitro, suppresses tumorigenicity (Tanaka et al., 1991) . Two candidate colon tumour suppressor genes, DCC and MCC on chromosomes 18 and 5 respectively, have been identified (Fearon et al., 1990; Kinzler et al., 1991) .
Most HCC are associated with chronic HBV infection. The HBV genome is integrated into the host DNA and many studies have detailed sites of integration looking for a consistent pattern and/or changes which might activate oncogenes. No consistent pattern has been found (Di Bisceglie, 1989) . Loss of specific segments of chromosomal DNA, however, has been shown including regions on chromosomes 4, 11 and 13 (Buetow et al., 1989; Wang et al., 1986) (Sambrook et al., 1989) . Samples were digested with the appropriate restriction endonuclease and were size fractionated by electrophoresis through 0.6-0.9% agarose gels. The DNA was transferred to Hybond-N hybridisation filters (Amersham) according to the manufacturer's specifications. DNA probes were radiolabelled with alpha-32P-dCTP (3,000 Cimol ') by the random hexanucleotide primer method (Feinberg & Vogelstein, 1983) to a high specific activity. Hybridisations were performed at 650C in 1% SDS, 1 M NaCl and 5% dextran sulphate (W:V) for 16-24 h. Filters were washed to stringency of 2 x SSC 1% SDS (W:V) at 640C and were autoradiographed at -70°C using Fuji: RX-L X-ray film.
The detection of chromosomal DNA loss depends upon demonstrating a difference in restriction fragment length polymorphism (RFLP) between tumour and non-tumour ('normal') DNA. Most of the probes used were selected because they are hypervariable, that is the majority of individuals will be heterozygous and hence informative at these loci (Wong et al., 1987) . A deletion in the region studied may then be seen as a loss of a band (or loss of intensity of a band). In this study we used 22 probes for chromosomes 1, 4, 5, 7, 9, 11, 12, 13, 14, 16, 17, 18 and 20 and of these 12 were hypervariable (Table I Previous work on colorectal adenomas and carcinomas has shown that the chromosome 5 region (5q21-22) encompassing the familial adenomatous polyposis coli (APC) gene is deleted in inherited and sporadic colorectal cancer (Miyaki et al., 1990) . For this reason we compared the pattern of allele loss in non-cirrhotic HCC with that of colorectal liver secondaries using various probes for chromosome 5q (Figure 2 ). Table II shows that patients with non-cirrhotic HCC had no allele loss when screened with probes mapped to regions of the chromosome other than 5q35-qter. On the other hand only two of five patients with colorectal liver metastases (informative with probe lambda MS8) showed allele loss in that region, but the majority of these patients showed allele loss with probes from 5q21-22, the region of the chromosome associated with colorectal cancer. (Sager, 1989) . The presence of a tumour suppressor gene locus on the short arm of chromosome 5 has not been previously reported and may be important in cirrhotic HCC. It is interesting that the pattern of chromosomal deletion in HCC shown so far correlates more on the present or absence of liver cirrhosis rather than the presence or absence of HBV infection. Since it was shown that tumours from patients who are seropositive for markers of HBV infection contain integrated HBV DNA sequences it has been argued that the viral genome may be involved in the induction and/or maintenance of the neoplastic phenotype (Chen et al., 1988) . The role of virally mediated oncogenesis in HCC has been widely studied, but yet, no conclusive results have emerged. Therefore it was interesting to find in our study no absolute differences in LOH pattern between HCC with or without HBV infection in spite of the differences in the aetiology and pathology processes. This lends support to the hypothesis that the development of cirrhosis (with its regenerative capacity) rather than the presence of integrated HBV genome is most important, although the number of patients studied to date is small. It remains to be seen whether tumour suppressor gene loss is different in HCC from cir- rhotic patients with different aetiology. It is of interest that in some cases we have been able to compare DNA from lymphocytes with that from non-tumorous cirrhotic liver, but as yet no allele loss (pre-malignant loss) has been detected (data not shown).
Relatively few chromosome studies have been carried out on HCC, but investigations on HCC cell lines showed involvement of chromosome 5, regions p14 and q31-33 in rearrangement or deletion (Simon et al., 1982; Simon & Knowles, 1986) . Of particular relevance is a chromosome 5 (q34) rearrangment in direct preparations from an HCC arising in a patient without evidence of HBV infection (Simon et al., 1990) . In other studies (Buetow et al., 1989; Zhang et al., 1990 ) frequent allele losses were found on chromosomes 4 and 16 in both HBV positive and negative HCC. Tsuda et al. suggested that LOH on chromosome 16 represents tumour progression. Our own study did not show LOH on chromosomes 4q, 16p or 16q. This could reflect either the difference in probes used or a difference in the stage of the tumours studied. None of our patients had extrahepatic tumour spread and all underwent 'potentially curative' resection of the tumours. In agreement with other workers (Kiechle-Schwarz et al., 1990), we have found no evidence for allele loss on lip. A literature survey did not reveal previous screening of the terminal region of 5q in HCC. In a very recent study (Fujimori et al., 1991) allelic loss was reported in HBV negative HCC in the region 5q21 (D5S84), but they did not mention the screening of 5q35-qter.
The comparison of the pattern of LOH on chromosome 5 between patients with non-cirrhotic HCC and patients with colorectal liver secondaries suggests that the loci are different in the two types of malignancies. The LOH in carcinoma of the colon peaks at the region 5q21 -22 while the LOH in non-cirrhotic HCC is at 5q35 qter. A larger number of samples needs to be tested to confirm this preliminary finding. Future work will also aim to identify and characterise the gene associated with non-cirrhotic HCC.
In conclusion, this study suggests that one of the tumour suppressor genes in non-cirrhotic HCC could be located on chromosome 5 and appears to be distinct from the locus of the familial adenomatous polyposis coli (APC) gene.
